Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial

IMPORTANCE: The port delivery system (PDS) with ranibizumab has demonstrated noninferior and equivalent efficacy compared with monthly intravitreal injections of ranibizumab, an anti–vascular endothelial growth factor (VEGF) agent, in patients with neovascular age-related macular degeneration (nAMD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Margaret A., Kapre, Audrey, Kaufman, Derrick, Kardatzke, David R., Rabena, Melvin, Patel, Shienal, Bobbala, Ashwini, Gune, Shamika, Fung, Anne, Wallenstein, Gene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204622/
https://www.ncbi.nlm.nih.gov/pubmed/35708706
http://dx.doi.org/10.1001/jamaophthalmol.2022.1091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204622/
https://www.ncbi.nlm.nih.gov/pubmed/35708706
http://dx.doi.org/10.1001/jamaophthalmol.2022.1091

Ejemplares similares